Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniaeSARS-CoV-2 변이체 및 폐렴 연쇄상 구균에 대한 다당류-단백질-접합 나노입자 백신의 합리적인 개발Article Published on 2022-05-012022-09-11 Journal: Advanced Materials (Deerfield Beach, Fla.) [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 폐렴구균 감염증, [키워드] Against backbone capsular capsular polysaccharide caused Cellular immune response cellular immune responses chemical conjugation clinical evaluation COVID-19 COVID-19 pandemic cross-neutralize death development Diseases domain exhibit Final helper cell highlighting humoral immune responses immunization induce Infection Infectious diseases mice Mortality mouse-adapted strain murine models nanoparticle nanoparticle vaccines omicron other infectious diseases polysaccharide potency Prevent RATs RBD Receptor binding domain rhesus macaques S. pneumoniae S. pneumoniae serotype type 14 SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant serotype serum Spike protein Streptococcus pneumoniae Support T helper cell the SARS-CoV-2 thermal stability Type vaccination Vaccine vaccine platform variant VOCs [DOI] 10.1002/adma.202200443 PMC 바로가기 [Article Type] Article
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell responseCOVID-19 백신 접종에 대한 면역 반응은 백신 주도의 발산 T 세포 반응을 통한 질병 통제 및 항골수종 요법에 의해 약화됩니다.Article Published on 2022-05-012022-09-11 Journal: British Journal of Haematology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] administration anti-CD38 Anti-spike anti-spike antibody antibody Antibody Response Antigen B-cell Bacterial blood sample Blood samples Cellular immune response cellular response Clinical significance COVID-19 vaccination COVID-19 vaccine disease disease severity Gender humoral humoral immune response immune responses interferon gamma male maturation Myeloma Patient patients Pfizer-BioNTech positive positive result predicted produced Prospective Study Protein provided reported required respond poorly response serology study cohort T-cell Response therapy vaccination Vaccine vaccine dose Viral [DOI] 10.1111/bjh.18066 PMC 바로가기 [Article Type] Article
An overview on inactivated and live-attenuated SARS-CoV-2 vaccines불활성화 및 약독화 SARS-CoV-2 백신에 대한 개요Review Published on 2022-05-012022-09-11 Journal: Journal of Clinical Laboratory Analysis [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse effects antigenic attenuated vaccine benefit Bharat Cell culture Cellular immune response China clinical trials component components coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine deaths effective Efficiency Features followed by Health Organization humoral Humoral and cellular immune responses immune responses inactivated Inactivated vaccine Infection landscape Phase 3 produced producing Record report review Safe SARS-CoV-2 SARS-CoV-2 vaccine severe acute respiratory syndrome Coronavirus similarity Sinopharm Sinovac storage the vaccine Transport trials Vaccine vaccine candidate vaccine platform Vaccines virion virus particle WHO World Health Organization worldwide pandemic Wuhan [DOI] 10.1002/jcla.24418 PMC 바로가기 [Article Type] Review
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod세 번째 COVID-19 백신 접종에 대한 면역 반응은 핀골리모드로 치료받은 다발성 경화증 환자의 림프구 수와 관련이 있습니다Randomized Controlled Trial Published on 2022-05-012022-09-11 Journal: Journal of Neurology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Absolute lymphocyte count adaptive adaptive cellular immunity BNT162b2 BNT162b2 vaccine both groups Cell Cellular immune response cellular immunity clinical trial correlated COVID-19 COVID-19 vaccination COVID-19 vaccine develop dose Efficacy fingolimod groups humoral Humoral immunity IgG IgG antibody IgG immune response immune response immune responses in both groups lymphocyte Lymphocyte count majority memory memory B memory B cell Multiple multiple sclerosis non-responder Patient patients patients treated Pfizer positive Protective Randomized randomized clinical trial relapsing SARS-CoV-2 vaccination SARS-CoV-2 vaccine single-center Specific T cell therapy Third BNT162b2 SARS-CoV-2 vaccine dose. Treatment two groups Vaccine were assessed [DOI] 10.1007/s00415-022-11030-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Induction of humoral and cellular immune responses to COVID-19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workersCOVID-19 mRNA 및 벡터 백신에 대한 체액 및 세포 면역 반응의 유도: 불가리아 의료 종사자를 대상으로 한 전향적 코호트 연구Article Published on 2022-05-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] advanced age age anti-SARS-CoV-2 immune responses anti-SARS-CoV-2 vaccine anti-SARS-CoV-2 vaccines BNT162b2 Bulgarian cellular Cellular immune response circulating Cohort comparable Complete coronavirus disease Coronavirus disease 2019 correlated Course COVID-19 COVID-19 vaccine Donor donors dose Enumeration evaluated healthcare worker humoral humoral immune response IFNγ IgA immune responses Immunity immunization Immunoglobulin immunoglobulin A increased risk induce induction Infection Installing interferon gamma Longevity Messenger RNA mRNA mRNA vaccine Neutralizing activity neutralizing antibody overcome Pandemics participant peaking priming prospective cohort study protective immunity Receptor-binding domain SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 specific T-cell significantly single dose T cell T cells tested Vaccine vaccine cohort virus-neutralizing virus-neutralizing antibody virus-neutralizing antibody. [DOI] 10.1002/jmv.27572 PMC 바로가기 [Article Type] Article
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques원숭이의 SARS-CoV-2 오미크론 변종에 대한 백신 보호Article Published on 2022-04-282022-09-11 Journal: Cell [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus antibody Antibody titer Antibody titers B.1.1.529 BNT162b2 BNT162b2 vaccine Bronchoalveolar lavage CD8+ T cell Cellular immune response contribute correlated cynomolgus macaques demonstrated Efficacy heterologous prime-boost High-dose homologous humoral immune responses macaque macaque. moderate mRNA mRNA-based mutated nasal swabs neutralizing antibody titers omicron populations question raised regimen respiratory response robust SARS-CoV-2 SARS-CoV-2 variant Spread T cell T cell responses the SARS-CoV-2 These data undetectable upper respiratory tract Vaccine Vaccines variant virus [DOI] 10.1016/j.cell.2022.03.024 PMC 바로가기 [Article Type] Article
Markers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan일본에서 BNT162b2 mRNA COVID-19 백신의 효과를 나타내는 메모리 CD8 T 세포의 마커Article Published on 2022-04-282022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료기술, [키워드] Affect anti-S antibody Antibody titers Antigen BNT162b2 BNT162b2 mRNA BNT162b2 vaccine boost CD107a CD38 CD8 CD8, vaccine CD8+ cell CD8+ cells CD8+ T cell CD8+ T cells Cell Cellular immune response cellular immune responses cellular immunity COVID-19 CTL Effect effector cell effector cells Efficacy elicit elicited environmental factor evaluate expression female Frequency function functions Genetic granzyme B immune responses intensity investigated Japan Japanese KLRG1 male males marker markers memory memory CD8+ T cells mRNA vaccination nucleoside nucleoside-modified mRNA pentamer positive cells positively correlated precursor proliferation Protein provide response S protein SARS-CoV-2 spike glycoprotein second vaccination serum Sex difference spike glycoprotein T cell T cell proliferation T cells Vaccine was increased [DOI] 10.3389/fimmu.2022.836923 PMC 바로가기 [Article Type] Article
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity저용량 SARS-CoV-2 S-삼량체(에멀젼 보조제 유도 Th1 편향 보호 면역 포함)Article Published on 2022-04-282022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 binding addition adjuvant alum aluminum aluminum hydroxide Antibody Response Antigen Antisera B cell B cells Beta binding affinity Cellular immune response clinical testing comparable Complete COVID-19 pandemic Delta demonstrated different dose different doses effective Efficacy Emulsion ENhance evaluated exhibit feasible follicular Germinal center herd immunity humoral immune response hydroxide immune responses Immunity immunogenicity induce induced Infection Lineage live SARS-CoV-2 low dose lower dose mass vaccination mice Mutation Neutralizing antibodies neutralizing antibody prefusion Prevent produced Protective protein subunit vaccine rodent rodents Safe SARS-CoV-2 Subunit vaccine Support sustained SWE T-cell T-cell responses T-cells Tfh the antibody response These data trimer utility vaccination Vaccinations Vaccine variant variants Viral viral infection viral spread were assessed [DOI] 10.3390/ijms23094902 PMC 바로가기 [Article Type] Article
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2BNT162b2 백신 접종 후 의료 종사자의 SARS-CoV-2 면역 장애 예측자Article Published on 2022-04-142022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] antibody Antibody titers BNT162b2 CD4 CD8 Cellular immune response cellular immune responses cellular immunity comparable Concentration convalescent detectable did not produce effective frequencies Frequency healthcare healthcare worker Healthcare workers hospital humoral humoral immune response IgG immune response immune responses Immunosuppression increased risk individual infection with SARS-CoV-2 median organ pandemic post vaccination PROTECT recipients reduced required Responder risk factor Risk factors SARS-CoV-2 SARS-CoV-2 immunity seroconversion rate significantly higher solid organ spike IgG Standard of care subject T cell T cell response T cell responses vaccination Vaccine was measured yielding [DOI] 10.1038/s41598-022-10307-8 PMC 바로가기 [Article Type] Article
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVClinical Trial Published on 2022-04-082022-10-04 Journal: JCI Insight [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, [키워드] ACE-2 Adaptive immunity AIDS/HIV Antiretroviral therapy AZD1222 baseline Beta coronaviruses CD4 Cell-mediated immunity Cellular immune response ChAdOx1 nCoV-19 Cohort correlated COVID-19 cross-reactive detectable dose Duration Evidence greater HIV HIV-uninfected humoral IFN-γ ELISPOT IgG ELISA immune response Immunity individual majority male participant marker Meso Scale Discovery neutralization no significant difference prevaccination regimen response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike serology Support T cell T cell proliferation T cell response T cells Trial undetectable vaccinate vaccination variants of concern viral loads with HIV [DOI] 10.1172/jci.insight.157031 PMC 바로가기 [Article Type] Clinical Trial